ArticleJournal of immune based therapies and vaccines2006
Cellular metabolism as a basis for immune privilege.
Article in Journal of immune based therapies and vaccines, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 31 citations in OpenAlex.
- Precision enhancement of CAR-NK cells through non-viral engineering and highly multiplexed base editing.Journal for immunotherapy of cancer · 2025Article
- Professional phagocytes are recruited for the clearance of obsolete nonprofessional phagocytes in theFrontiers in immunology · 2024Article
- Article
- Adenovirus-mediated gene delivery restores fertility in congenitally infertile female mice.The Journal of reproduction and development · 2022Article
- Elevation of Serum Cytokine Profiles and Liver Metabolomic Normalization in Early Convalescence of COVID-19 Patients.Frontiers in medicine · 2021Article
- Pharmacological inhibition of carnitine palmitoyl transferase 1 inhibits and reverses experimental autoimmune encephalitis in rodents.PloS one · 2020Article
- Transforming Growth Factor Beta Signaling in Dendritic Cells Is Required for Immunotolerance to Sperm in the Epididymis.Frontiers in immunology · 2018Article
- IFN-γ fails to overcome inhibition of selected macrophage activation events in response to pathogenic mycobacteria.PloS one · 2017Article
- Coenzyme Q10 depletion in medical and neuropsychiatric disorders: potential repercussions and therapeutic implications.Molecular neurobiology · 2013Review
- Altered local and systemic immune profiles underlie lymph node metastasis in breast cancer patients.International journal of cancer · 2013Article
- Changing the energy of an immune response.American journal of clinical and experimental immunology · 2013Article
- Model-driven multi-omic data analysis elucidates metabolic immunomodulators of macrophage activation.Molecular systems biology · 2012Article
- The regulation and turnover of mitochondrial uncoupling proteins.Biochimica et biophysica actaReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We hypothesize that the energy strategy of a cell is a key factor for determining how, or if, the immune system interacts with that cell. Cells have a limited number of metabolic states, in part, depending on the type of fuels the cell consumes. Cellular fuels include glucose (carbohydrates), lipids (fats), and proteins. We propose that the cell's ability to switch to, and efficiently use, fat for fuel confers immune privilege. Additionally, because uncoupling proteins are involved in the fat burning process and reportedly in protection from free radicals, we hypothesize that uncoupling proteins play an important role in immune privilege. Thus, changes in metabolism (caused by oxidative stresses, fuel availability, age, hormones, radiation, or drugs) will dictate and initiate changes in immune recognition and in the nature of the immune response. This has profound implications for controlling the symptoms of autoimmune diseases, for preventing graft rejection, and for targeting tumor cells for destruction.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.